Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Rhea-AI Summary
Heron Therapeutics (Nasdaq: HRTX) will report third quarter 2025 financial results on Tuesday, November 4, 2025, and will host a conference call and live webcast at 8:30 a.m. ET to discuss results and recent business highlights.
Participants can join by phone via a registration link that provides dial-in details; callers are encouraged to dial in 15 minutes early. The webcast will be available in the Investor Relations section at www.herontx.com. An archive of the teleconference and webcast will be available on the website for 60 days after the call.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, HRTX declined 8.46%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron’s website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
FAQ
When will Heron Therapeutics (HRTX) report Q3 2025 results and hold the conference call?
How can investors access the Heron Therapeutics (HRTX) November 4, 2025 earnings call?
Is there a recommended time to join the Heron Therapeutics (HRTX) conference call on November 4, 2025?
Will the Heron Therapeutics (HRTX) Q3 2025 webcast be available after the live call?
What topics will Heron Therapeutics (HRTX) cover during the November 4, 2025 call?
Where on the Heron Therapeutics (HRTX) site can I find the webcast and archive for the Q3 2025 call?
